NEW YORK -- (BUSINESS WIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of four new additions to the senior management team. As Actinium’s drug candidates continue to advance through the clinic, these hires are timely and expected to enable the Company to maximize the value of its assets. Capabilities are being added in clinical operations, regulatory affairs, quality assurance, finance and communications. Actinium gains business development and investor relations expertise as well, as the Company raises its profile in the investment community. These four hires bring to the Company a robust and complementary set of healthcare industry experience, product development skills, regulatory compliance, and communications acumen.
Evan Smith, CFA was appointed Vice President, Investor Relations and Finance. In his new role, Evan will be a member of the leadership team and will report to Sandesh Seth, Chairman of Actinium. Evan will be responsible for executing the Company’s investor relations and corporate communications program to effectively reach key audiences in order to support the Company’s corporate and strategic goals. In addition, Evan will provide high-level financial support for Actinium’s strategic growth initiatives.
David Gould, MD has joined as Senior Vice President, Finance and Corporate Development. In his new role, David will be a member of the leadership team and will report to Sandesh Seth, Chairman of Actinium. David will be responsible for managing corporate and strategic development activities, including identification and evaluation of new business opportunities such as product licensing. In addition, David will interface with institutional investors, research analysts and clinical opinion leaders.
Dennis Earle, MS is serving as Senior Vice President of Clinical Operations. In his new role, Dennis will be a member of the leadership team and will report to Kaushik J. Dave, Ph.D., President and CEO of Actinium. Dennis is responsible for the high quality and timely execution of our clinical development plans for both Actimab-A and Iomab™-B. Additionally, Dennis is managing New Product Planning efforts for both Actimab-A and Iomab™-B to ensure that commercial considerations are accounted for in the execution of our clinical development plans.
Gerald Orehostky is joining as Vice President of Quality and Regulatory Affairs. In his new role, Jerry will be a member of the leadership team and will report to Kaushik J. Dave, Ph.D., President and CEO of Actinium. Jerry is responsible for GMP quality policies and systems to promote, facilitate and assure sustainable compliance with all regulatory standards. He will ensure the safe and consistent manufacture of Actinium’s radiopharmaceuticals and oversee submissions to and interactions with the FDA.
"Following our strong progress in the development of our lead compound and our pipeline, we are pleased to have these four professionals join our growing management team. This expansion of operational strengths, communications and financial expertise comes at an important inflection point for Actinium," said Dr. Kaushik J. Dave, President and CEO. "We anticipate continued momentum and growth at the company and look forward to accelerating progress in drug development, investment efforts and overall business strategy."
Evan Smith, CFA joins Actinium with more than 20 years of experience in investor relations and corporate communications having advised a broad range of clients from Fortune 500 to early stage development companies in the biopharmaceutical and healthcare markets. Evan was previously head of investor relations for inVentiv Health and held senior positions at MWW Group, Chandler Chicco Companies and FTI Consulting. Evan also brings experience as an investment analyst and portfolio manager having worked as Fred Alger Management and Gintel Equity Management, both institutional investment firms. Evan earned a B.A. from University at Albany, State University of New York and a M.B.A. from the Fuqua School of Business at Duke University.
David Gould, MD has 14 years of healthcare sector investment experience across the life sciences spectrum. Most recently, he was a Principal and Partner at Merlin Nexus, a specialized late-stage private equity firm which invested in emerging public and late-stage private biotechnology and medical device companies. There he was part of an investment team which generated consistently strong, benchmarked returns, driven in part by a disciplined focus on clinical data and unmet medical need, including oncology. Prior to that, David was a Vice President at Dresdner Kleinwort Capital, as part of their Global Private Equity healthcare investment team based in New York and London. He gained additional experience there in pharmaceutical equity research. Dr. Gould received a MD from Jefferson Medical College, of Thomas Jefferson University in Philadelphia. He also received a M.B.A. in Finance from Stern School of Business, New York University and a B.S. in Molecular Biology from the University of Wisconsin – Madison.
Dennis Earle has more than 20 years of experience in clinical development and program management within the biopharmaceutical industry. Most recently, Mr. Earle held the position of Vice President Clinical Operations & Project Management at Onconova Therapeutics. At Onconova, he assumed responsibility for the oncology clinical studies, including solid tumor and hematologic indications; notably, acute myeloid leukemia (AML) and the global Phase 3 program in myelodysplastic syndrome (MDS). Prior to that, Mr. Earle was Head of Program Management & Strategic Planning at Adolor, Vice President of Clinical Operations & Program Management at Intercept Pharmaceuticals. Prior to that, Mr. Earle was the Executive Director, Clinical Affairs at Palatin Technologies. Initially, Dennis served in senior management positions at Covance including Global Project Director-Oncology. Mr. Earle has received a M.B.A. from Saint Joseph’s University, a M.S. in Biotechnology from Johns Hopkins University and a B.A. in Biochemistry & English from Rutgers University. Additionally, Mr. Earle is certified as a Project Management Professional (PMP) through the Project Management Institute.
Jerry Orehostky has more than 25 years of experience within the pharmaceutical, biotechnology and medical device industries overseeing global quality systems and operations functions. This included domestic and international drug development programs and manufacturing operations as well as the direction of United States and European regulatory activities. Most recently he was Vice President of Regulatory Affairs and Quality Operations at Antares Pharma. Prior to joining Antares Pharma, Mr. Orehostky served as Vice President of Quality Operations of Discovery Laboratories Inc. Prior to that, he served as an Executive Director of Quality Assurance and Regulatory Affairs at Palatin Technologies. He also previously served as Director, Worldwide Quality Services at Schering-Plough and Director, Quality Operations and Regulatory Compliance at Vivus. Mr. Orehostky received a MBA from Rider University, a B.A. in Natural Science and Mathematics from Thomas Edison State College and has obtained his Quality Engineer Certification.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.